Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration

Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration

Bibliographic Details
Main Author:	Jay Kumar Chhablani
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2010-01-01
Series:	Oman Journal of Ophthalmology
Online Access:	http://www.ojoonline.org/article.asp?issn=0974-620X;year=2010;volume=3;issue=2;spage=99;epage=100;aulast=Chhablani

Similar Items

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
by: Pukhraj Rishi, et al.
Published: (2011-02-01)

Combined photodynamic therapy and intravitreal bevacizumab as treatment for nonresponsive myopic choroidal neovascularization
by: Jay Kumar Chhablani
Published: (2010-01-01)

Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma
by: Rodney J Morris, et al.
Published: (2011-01-01)

Verteporfin photodynamic therapy combined with intravitreal ranibizumab in neovascular age-related macular degeneration: 24-month follow-up
by: Rosalia Giustolisi, et al.
Published: (2014-09-01)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
by: So Young Han, et al.
Published: (2015-02-01)

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
by: Mamdouh M Kabeel, et al.
Published: (2008-03-01)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
by: Wataru Matsumiya, et al.
Published: (2011-01-01)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
by: Partha Biswas, et al.
Published: (2011-01-01)

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy
by: Miguel Hage Amaro, et al.
Published: (2013-06-01)

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
by: Williams PD, et al.
Published: (2012-09-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021-06-01)

A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
by: Sivaprasad, S, et al.
Published: (2011)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
by: Tomoko Nakamura, et al.
Published: (2012-01-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Single intravitreal ranibizumab for myopic choroidal neovascularization
by: Shatriah I, et al.
Published: (2011-08-01)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
by: Gallemore RP, et al.
Published: (2017-01-01)

Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration
by: Azarmina Mohsen, et al.
Published: (2007-06-01)

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
by: Ellabban AA, et al.
Published: (2012-05-01)

Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
by: Sarah Sabour-Pickett, et al.
Published: (2013-01-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01)

Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia
by: Pukhraj Rishi, et al.
Published: (2011-01-01)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
by: Karagiannis D, et al.
Published: (2017-06-01)

Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration
by: Hüseyin Dündar, et al.
Published: (2014-10-01)

Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularization
by: Hussain Nazimul, et al.
Published: (2006-01-01)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
by: Ki Woong Bae, et al.
Published: (2022-11-01)

Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for neovascular age-related macular degeneration
by: Cihan Ünlü, et al.
Published: (2015-08-01)

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization Secondary to Endogenous Endophthalmitis
by: Shwu-Jiuan Sheu
Published: (2009-11-01)

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
by: Neeraj Pandey, et al.
Published: (2013-01-01)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
by: David R. Griffin, et al.
Published: (2014-01-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)

Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
by: Jose Navarro-Partida, et al.
Published: (2021-09-01)

Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies
by: Audrey Yan, et al.
Published: (2025-01-01)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
by: Hamidreza Torabi, et al.
Published: (2018-01-01)

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
by: Ki Won Jin, et al.
Published: (2021-07-01)

Intravitreal Ranibizumab for Treatment of Posttraumatic Choroidal Neovascularization: a Case Report
by: A. N. Kulikov, et al.
Published: (2021-10-01)

Clinical Efficacy of Intravitreal Ranibizumab in Early and Mid-Idiopathic Choroidal Neovascularization
by: Chuanfeng Fan, et al.
Published: (2014-01-01)

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome
by: İrfan Perente, et al.
Published: (2018-04-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)